Inopressors (particularly norepi) are the most frequently utilized vasoactive agents in CS; however, several factors including CS etiology drive differential practice patterns for vasoactive selection. @sidpatelmd #AHA24

New data from the Critical Care Cardiology Trials Network & @UmichCVC shows significant variation in vasoactive medication use in the treatment of cardiogenic shock across different CICU centers. 23% of variation was explained by local institutional practice alone. @davyhamilton1 @sidpatelMD #AHA24

"Does lowering LDL-C to very low levels result in long-term cognitive impairment?" 🧠🫀 I've heard this question many times. Now we have long-term data. A 🧵 on our new NEJM Evidence paper: evidence.nejm.org/doi/full/10.10… TIMI Study Group Robert Giugliano Michelle O'Donoghue

heart.org/en/news/2024/1… American Heart Association

In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN #AFib

We authored the editorial “Science Behind the Study” for NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of the Factor XI inhibitor abelacimab in patients with atrial fibrillation. Collaborating with the journal’s illustrator on the figure, which explains the

The amazing Dr. David Morrow talking at Smidt Heart Institute at Cedars-Sinai the improvement in care of patients with the evolution of the CICU 💥 CCU started at Cedars-Sinai! 👏🏽 🫀 Overtime what is in CCU has evolved from ACS 🫀 Improved outcomes w/ high intensity staffing (not high intensity statin!)

There doesn’t appear to be a floor with LDL—💥 lower is better, even in the elderly. Check out our work in JACC Journals sciencedirect.com/science/articl…

Updated 2025 ACC/AHA ACS Guidelines now released! Congratulations to Michelle O'Donoghue, TIMI Senior Investigator, who served as Co-Chair. ahajournals.org/doi/10.1161/CI…

Now out in Nature Medicine, we developed an Endothelial Cell PRS for CAD that: 1) Quantifies a currently immeasurable axis of CAD risk 2) Identifies individuals who are LDL-sensitive 3) Establishes which Pts will have greatest CV benefit from early & aggressive lipid lowering

Thanks so much JACC Journals for showcasing our study led by 🌟Sina Rashedi w support from🗺️experts: OAC monotherapy is✅for most pts w AF + stable CAD. Awaiting data from #AQUATIC. Do the results apply to other indications such as mechanical valves or VTE + stable ASCVD?🤔